Organic Process Research & Development 2004, 8, 266−270
Communications to the Editor
An Improved and Single-Pot Process for the Production of Pantoprazole
Substantially Free from Sulfone Impurity
Vijayavitthal T. Mathad,* Shanmugam Govindan, Naveen Kumar Kolla, Madhavi Maddipatla, Eswaraiah Sajja, and
Venkataraman Sundaram
Department of Research and DeVelopment, Dr. Reddy’s Laboratories Ltd., Bulk ActiVes, Unit III, Plot No. 116,
S. V. Co-Op. Ind. Estate, Bollaram, Jinnaram, Medak Dist 502 325, Andhra Pradesh, India
Abstract:
Scheme 1
Pantoprazole (1), a substituted benzimidazole derivative, is an
irreversible proton pump inhibitor, essentially used for the
prevention and treatment of gastric acid-related diseases. The
process for its preparation generally suffers from the drawback
of producing a potential sulfone impurity (5). The present work
details a report of the journey towards the development of a
simple, single-pot process for the production of pantoprazole,
substantially free from sulfone impurity (5). The detailed study
of the different parameters affecting the purity and yield of
the compound has been presented.
Pantoprazole (1) is an oral, pharmaceutically active
1
compound having promising anti-ulcer activity and belongs
to the class of 2-[[(2-pyridinyl)methyl]sulfinyl]-1H-benz-
imidazoles. In general this class are used for the prevention
and treatment of gastric acid-related diseases. Literature
the later is generated due to the over-oxidation of the
sulfoxide derivative (1). However the N-oxide impurity was
observed always in the range from 0.02 to 0.05% in the lab
experimental studies, whereas sulfone was seen as a potential
impurity. Due to similarity of the sulfone compound structure
with that of the parent compound, complete removal of 5
proved problematic.
2
studies reveal different methods for the preparation of
3
2
pantoprazole. The general process for the preparation of
pantoprazole involves condensation of thiol derivative 2 with
chloromethyl pyridine derivative 3 in the presence of
inorganic base to yield 5-(difloromethoxy)-2-[[(3,4-dimethoxy-
5
Different oxidizing agents such as peracids, peresters,
2
-pyridinyl)methyl]thio-1H-benzimidazole (4), which upon
and peroxides were employed for the conversion of the
sulfide derivative (4) to the sulfoxide derivative (1); preferred
conditions mentioned in the literature included oxidizing the
sulfide derivative (4) with an approximately equimolar
quantity of the oxidizing agent in an organic solvent. The
further oxidation with a suitable oxidizing agent leads to the
desired pantoprazole (1) as shown in Scheme 1.
The most important and critical step in the process is the
oxidation wherein there are chances of formation of two
impurities viz., pantoprazole N-oxide (6) and pantoprazole
sulfone (5) as these are mentioned in the recently published
6
most recent version of the process involved the oxidation
4
of 4 using tert-butyl hydroperoxide and VO(acac) . Yet
4
7
analytical drug profile. The former is formed due to the
oxidation at the nitrogen center of the pyridine moiety, and
another version involved oxidation of 4 with m-chloroperoxy
benzoic acid followed by successive pH adjustments to yield
pantoprazole in the organic layer. Concentration of the
organic solvent followed by crystallization in acetone resulted
in the formation of fine solid crystals. All the processes
described previously suffered from the drawback of produc-
ing a considerable amount of 5. Also, a second major
drawback in many of the previous processes was the usage
of heavy metal reagents, such as vanadium, which may prove
*
Corresponding author. Fax: 91 8458 279619. Telephone: 91 8458 279713.
E-mail: vijayavitthalm@drreddys.com.
(
1) (a) Kormer, W.; Postius, S.; Riedel, R.; Simon, W. A.; Hanauer, G.; Brand,
U.; Goenne, S.; Parsons, M. E. J. Pharmacol. Exp. Ther. 1990 1, 254. (b)
Bernhard, K.; Ernst, S.; Joerg, S. B.; Alexander, W. S.; Uwe, K.; Hartmann,
S.; Georg, R.; Volker, F.; Kurt, K. J. Med. Chem. 1992, 35, 1049.
2) Kohl, B.; Sturm, E.; Rainer, G. U.S. Patent 4758579, 1985; EP Patent
(
(
1
66287, 1985.
3) (a) Kormer, W.; Kohl, B. Drugs Future 1990, 15, 801. (b) Bekhazi, M.;
Zoghbi, M.; WO 97/29103, 1997. (c) Brennan, J. P.; Turner, A. T. WO
9
9/47514 A1, 1999. (d) Cheng, M.; Wang, Q.; Pan, L. Faming zhuanli
(5) Alan, E. M.; Daniel, P. B.; Daniel, L. F.; Hui, L.; Clara, I. V. U.S. Patent
5,945,425, 1999.
(6) Ilya, A.; Marioara, M. U.S. Patent 0036554 A1, 2003.
(7) Broeckx, R.; Laurent, M.; De Smaele, D.; Leurs, S.; Marcel, H. WO 03/
008406 A1.
gongkai shuomingshu, 1, 102, 411 (Cl. COID4501/12), 10 May 1995.
4) Adnan, A. B.; Lina, N. N.; Al Omari, M. M.; Nidal, H. D.; Mahmoud, K.
A.; Ahmad, M. A.; Jaber, A. M. Y. Anal. Profiles Drug Subst. Excipients
(
2
002, 29, 213.
2
66
•
Vol. 8, No. 2, 2004 / Organic Process Research & Development
10.1021/op034157y CCC: $27.50 © 2004 American Chemical Society
Published on Web 03/03/2004